Tag: clinical trials for cancer

10 Highlights for the Carcinoid and Neuroendocrine Tumor Community

• PET/CT using Gallium-68 DOTATOC captures hidden source of neuroendocrine cancer. “An investigational molecular imaging technique could be the key to finding the elusive primary tumor, say presenters at the 2015 Annual Meeting of the Society

Lexicon Pharmaceuticals Begins Phase 3 Clinical Trial of Telotristat Etiprate in Patients with Carcinoid Syndrome

Patients with metastatic carcinoid syndrome will have the opportunity to participate in a new Phase 3 clinical trial of Lexicon Pharmaceutical’s telotristat etiprate (LX1032), an oral drug candidate designed to treat carcinoid syndrome by reducing…

Now Recruiting: Carcinoid Syndrome Patients to Participate in Clinical Trial

Ipsen is recruiting patients with a history of carcinoid syndrome to participate in a clinical study to evaluate the effect of Somatuline® Depot (Lanreotide Autogel),  a somatostatin analog (SSTa) similar to octreotide, on the control of symptoms …

Multiple Endocrine Neoplasias (MEN) Patient Education Conference to Be Held at MD Anderson Cancer Center in June

MEN, carcinoid, and neuroendocrine tumor patients, family members, advocacy groups, physicians, and caregivers are invited to attend MD Anderson Cancer Center’s Multiple Endocrine Neoplasias Patient Education Conference on Saturday, June 26,…

Carcinoid Syndrome Clinical Trial to Be Featured on Webcast

Lexicon Pharmaceuticals’ clinical trial LX1032 for carcinoid syndrome will be among the clinical programs that are reviewed in-depth on April 8, 2010 when the company holds its Annual R&D Day from 7:30 to 11:00 am, Eastern Time, in New York City. …

Clinical Trial Recruiting Neuroendocrine Tumor Patients with Pheochromocytoma or Paraganglioma

Neuroendocrine tumor patients with malignant pheochromocytoma or paraganglioma are being sought for a multi-center clinical trial conducted by Molecular Insight Pharmaceuticals, Inc. In the New York area, one of the clinical trial sites is the Mount…